Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer

Clinical Cancer Research

Volumn 20, Issue 9, 2014, Pages 2312-2325

  Li, Xia ^a   Wan, Xuechao ^a   Chen, Hongbing ^c   Yang, Shu ^a   Liu, Yiyang ^a   Mo, Wenjuan ^a   Meng, Delong ^a   Du, Wenting ^a   Huang, Yan ^a   Wu, Hai ^a   Wang, Jingqiang ^a   Li, Tao ^b   Li, Yao ^a  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Department of Urology Hefei First People's Hospital ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; MICRORNA; MICRORNA 133B; PROSTATE SPECIFIC ANTIGEN; RNA; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANDROGEN; ANDROGEN RECEPTOR; MIRN133 MICRORNA, HUMAN; PROTEIN BINDING; PROTEIN TYROSINE KINASE; RB1CC1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHEMICAL ANALYSIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE; GENE TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RB1CC1 GENE; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; 3' UNTRANSLATED REGION; BINDING SITE; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; MORTALITY; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROSTATIC NEOPLASMS; RECURRENT DISEASE; TREATMENT OUTCOME; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANDROGENS; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICRORNAS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; RECEPTORS, ANDROGEN; RECURRENCE; RNA INTERFERENCE; TREATMENT OUTCOME;

EID: 84899738420     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1588     Document Type: Article

References (48)

1. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 2011;71: 1313-24.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Hyun JS. Prostate cancer and sexual function. World J Mens Health 2012;30:99-107.
4. Molitierno J, Evans A, Mohler JL, Wallen E, Moore D, Pruthi RS. Characterization of biochemical recurrence after radical prostatectomy. Urol Int 2006;77:130-4.
5. Li X, Huang Y, Fu X, Chen C, Zhang D, Yan L, et al. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer. Mutagenesis 2011;26:371-83.
6. Culig Z, Bartsch G. Androgen axis in prostate cancer. J Cell Biochem 2006;99:373-81.
7. Xiao J, Gong AY, Eischeid AN, Chen D, Deng C, Young CY, et al. miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. Prostate 2012;72:1514-22.
8. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008;14:417-24.
9. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE 2008;3:e4029.
10. Musiyenko A, Bitko V, Barik S. Ectopic expression of miR-126, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med 2008;86:313-22.
11. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al. An androgenregulated miRNA suppresses Bak1 expression and induces androgenindependent growth of prostate cancer cells. Proc Natl Acad Sci U S A 2007;104:19983-8.
12. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006;20:515-24.
13. Wong TS, Liu XB, Chung-Wai Ho A, Po-Wing Yuen A, Wai-Man Ng R, Ignace Wei W. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 2008;123:251-7.
14. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010;127:2804-14.
15. Hu G, Chen D, Li X, Yang K, Wang H, Wu W. miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol Ther 2010;10:190-7.
16. Qin W, Dong P, Ma C, Mitchelson K, Deng T, Zhang L, et al. MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. Oncogene 2012;31: 4067-75.
17. Townley-Tilson WH, Callis TE, Wang D. MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol 2010;42:1252-5.
18. Haas JD, Nistala K, Petermann F, Saran N, Chennupati V, Schmitz S, et al. Expression of miRNAs miR-133b and miR-206 in the Il17a/f locus is co-regulated with IL-17 production in alphabeta and gammadelta T cells. PLoS ONE 2011;6:e20171.
19. Chano T, Ikegawa S, Kontani K, Okabe H, Baldini N, Saeki Y. Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells. Oncogene 2002;21:1295-8.
20. Gan B, Guan JL. FIP200, a key signaling node to coordinately regulate various cellular processes. Cell Signal 2008;20:787-94.
21. Dahiya R, Perinchery G, Deng G, Lee C. Multiple sites of loss of heterozygosity on chromosome 8 in human breast cancer has differential correlation with clinical parameters. Int J Oncol 1998; 12:811-6.
22. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294:433-9.
23. Mo W, Zhang J, Li X, Meng D, Gao Y, Yang S, et al. Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancer. PLoS ONE 2013;8:e56592.
24. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007;27: 380-92.
25. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 1998;273:5939-47.
26. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, ChuTM, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
27. Li Y, Zhang D, Chen C, Ruan Z, Huang Y. MicroRNA-212 displays tumor-promoting properties in non-small cell lung cancer cells and targets the hedgehog pathway receptor PTCH1. Mol Biol Cell 2012;23:1423-34.
28. Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 2005;19:631-42.
29. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005;122:33-43.
30. Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 2009;383: 280-5.
31. Zhang D, Chen C, Li Y, Fu X, Xie Y, Huang Y. Cx31.1 acts as a tumour suppressor in non-small cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis. J Cell Mol Med 2012;16:1047-59.
32. Wang X, Guo Y, Yang S, Wang C, Fu X,Wang J, et al. Cellular and molecular mechanisms of photodynamic hypericin therapy for nasopharyngeal carcinoma cells. J Pharmacol Exp Ther 2010; 334:847-53.
33. Li T, Li RS, Li YH, Zhong S, Chen YY, Zhang CM, et al. miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 2012;187:1466-72.
34. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
35. Li T, Huang S, Dong M, Gui Y, Wu D. Prognostic impact of SUMOspecific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy. Urol Oncol 2013;31:1539-45.
36. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21: 2933-42.
37. Wang X. miRDB: a microRNA target prediction and functional annotation database with a Wiki interface. RNA 2008;14:1012-7.
38. Ikebuchi K, Chano T, Ochi Y, Tameno H, Shimada T, Hisa Y, et al. RB1CC1 activates the promoter and expression of RB1 in human cancer. Int J Cancer 2009;125:861-7.
39. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008;9:102-14.
40. Shenouda SK, Alahari SK. MicroRNAfunction in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 2009;28:369-78.
41. Patron JP, Fendler A, Bild M, Jung U, Muller H, Arntzen MO, et al. MiR-133b targets antiapoptotic genes and enhances death receptorinduced apoptosis. PLoS ONE 2012;7:e35345.
42. Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, et al. microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep 2012; 27:1967-75.
43. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009;60:167-79.
44. Tameno H, Chano T, Ikebuchi K, Ochi Y, Arai A, Kishimoto M, et al. Prognostic significance of RB1-inducible coiled-coil 1 in salivary gland cancers. Head Neck 2012;34:674-80.
45. Chano T, Ikebuchi K, Tomita Y, Jin Y, Inaji H, Ishitobi M, et al. RB1CC1 together with RB1 and p53 predicts long-term survival in Japanese breast cancer patients. PLoS ONE 2010;5:e15737.
46. Shariat SF, Svatek RS, Kabbani W, Walz J, Lotan Y, Karakiewicz PI, et al. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int 2008;101:232-7.
47. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
48. Li T, Gui Y, Yuan T, Liao G, Bian C, Jiang Q, et al. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy. BJU Int 2012;110:E1125-30.